The occurrence of galactorrhoea in four patients is of some interest. Prolactin levels in patients with acromegaly are raised in 27 % of cases (Franks et al., 1976) . In some cases this is due to suprasellar extension of the tumour and interference with the action of prolactin inhibiting factor. In others it is because there is an adenoma which contains two types of cell, one of which secretes growth hormone and the other prolactin (Corenblum et al., 1976) . The raised prolactin level is not necessarily associated with galactorrhoea.
NATURAL HISTORY
Information about the natural history of acromegaly, which has an important bearing on the management of patients, is incomplete. Wright et al. (1970b) retrospectively surveyed 194 patients who had attended a number of centres in London between 1939 and 1967. They reported that total deaths were twice the expected number, especially in the patients over 45 years of age, and exceeded that expected in relation to cardiac, respiratory, and cerebrovascular disorders. Mortality was also increased in patients with clinical diabetes. The present series has not been followed long enough to produce any meaningful findings about increased mortality. The length of the history in some of the patients suggests that acromegaly may be a relatively benign disease. Neverthe-'Furrowing of the skin of the scalp on the crown and back of the head. less, it seems that untreated acromegaly will ultimately shorten the patient's life. Eighteen patients in this series have died already, from causes shown in Table 5 
DIAGNOSIS
Acromegaly is often easy to diagnose on the characteristic facial appearance and the changes in the hands and feet. In milder cases the changes may be subtle and difficult to recognise. The first definitive diagnostic step is to measure the plasma or serum growth hormone level, and this may be done initially in the outpatient department. However, there are many factors-such as stress-which influence growth hormone levels, so it is better to have the patient in hospital for more definite diagnosis and to take the measurements at a consistent time. We take blood first thing in the morning, and have previously shown the variability of the basal growth hormone level in patients with acromegaly (Williams et al., 1975) . We therefore recommend at least three morning basal growth hormone measurements before a diagnosis is made. Occasionally the basal growth hormone level is raised by stress, so that the suppressibility of the raised level by glucose should be studied. If the rise is due to stress it should be suppressed to < 10 mU/l after 50 g glucose by mouth. In some patients the severity ofthe acromegaly may seem disproportionate to the level of growth hormone and it may be helpful to measure the 'integrated' growth hormone levels throughout the 24 hours (Daggett, 1976) . Discrepancies may remain between the apparent clinical severity and the growth hormone level, and perhaps in these patients the formation of somatomedin in the liver under the influence of growth hormone is either reduced or increased.
The levels of growth hormone in the 150 patients being reviewed are shown in Fig. 1 Table 6 . Conventional external irradiation is widely available but it lowers growth hormone level slowly, and probably in only about half the patients does it reach normal within the first four years (Hunter et al., 1974 (Williams et al., 1975) . Hardy (1973) in Montreal has reported that it is possible to remove the pituitary adenoma and leave some normal pituitary in situ.
Bromocriptine is now being used for the treatment of patients with acromegaly and can lower growth hormone levels and ameliorate symptoms. It is ineffective in more severe cases and some patients are reluctant to take tablets indefinitely (Thorner et al., 1975) . Somatostatin has been shown to reduce growth hormone levels in patients with acromegaly (Hall et al., 1973) , but it has to be given by injection and possibly produces some side effects; it does not seem to be a practical mode of treatment. Table 7 Results of transsphenoidal surgery with or without x-ray therapy in 88 patients with acromegaly insipidus in three, and one developed CSF rhinorrhoea which cleared up spontaneously in about 10 days. The other point of interest is the effect of this operation on other pituitary trophic hormones. The latest endocrine assessment of these 88 patients (Table 8) shows that 51 out of the 63 with a satisfactory response do not require any replacement therapy. Since these patients had often undergone other forms of treatment in the past it is perhaps more important to look at the changes in endocrine status that resulted from transsphenoidal surgery. Of those operated on successfully six lost all their trophic hormones (Table 9 ) and whereas some lost gonadotrophins others actually regained the ability to secrete them. There remains the problem of the 25 patients who have failed to respond satisfactorily to transsphenoidal surgery. Ten of them have been treated with deep x-ray therapy directed particularly to the region where it was thought that possibly the tumour had not been completely cleared. We are following the growth hormone levels in these patients and have noted that it is lowered to an encouraging extent at the end of the x-ray therapy. But the fall is only transient (Fig. 2) 1971 1972 1973 1974 1975 1976 Some patients had had x-ray therapy before undergoing surgery. These cases are rather more difficult to operate on because of the fibrosis and distortion in the pituitary fossa. When the response to operation has not been satisfactory further irradiation has not been given because of the risk of neoplastic change in the area. Seven patients had had yttrium implantation before the operation. This too makes the operation somewhat more difficult on account of fibrosis, but here we have an interesting possibility of a continuing fall in the growth hormone level after the operation as a result of vascular changes induced by the yttrium. This is illustrated by the results in one patient (Fig. 3) . Some of the remaining patients have X 1972 1973 1974 1975 1976 
Other patients
These included 11 patients who had previously been treated with surgery plus x-ray therapy (4), with x-ray therapy alone (5), or with x-ray therapy plus yttrium implantation (2). The last two were referred on account of a CSF leak which was successfully repaired. Two of these patients were referred when they had developed neoplastic change in the area of irradiation.
Four patients were treated with x-ray therapy. Two of these on follow-up show some fall in growth hormone level, but in neither has this reached the normal range. Eight patients have refused any kind of treatment. Active therapy was not recommended in nine patients for the following reasons: cardiomyopathy in three (of whom two have died), vascular disease in four (of whom three are known to have died), and carcinomatosis in two. Two patients are awaiting treatment. In 18 patients the condition is mild. They are continuing under observation, but four of them are being treated with bromocriptine.
BROMOCRIPTINE
In 1972 this drug was shown to lower the growth hormone level in patients with acromegaly. This was somewhat surprising because in normal subjects bromocriptine actually raises the level. The fall produced is only modest, but there is often dramatic improvement in the patient's symptoms. In this series bromocriptine has been given to 12 patients. Three of them with cardiomyopathy were regarded as being unfit for surgical treatment. In one the growth hormone level has fallen satisfactorily, but improvement of the cardiomyopathy is difficult to establish. In the other two patients the caidiac failure progressed without any response to bromocripine and they died. Five other patients were given bromocriptine after surgery, with or without x-ray thrapy, had failed to lower the growth hormone level to normal. Four of these had a transsphenoidal and one a transfrontal operation. The growth hormone levels in these have fallen but have not yet reached the normal range. Bromocriptine has also been given to four mild cases of acromegaly in whom surgery was not recommended, and in these patients there has been an encouraging fall in growth hormone level. Our experience at present suggests that bromocriptine is not sufficient treatment for patients with high levels of growth hormone but may be used to supplement other treatments. It may also be worth considering in the case of older patients with mild acromegaly.
These patients have been treated in collaboration with Mr R. A. Williams, who performed the transsphenoidal operations. Transfrontal surgery was undertaken by Mr J. Andrew. The radioimmunoassays were performed by Professor R. P. Ekins and the staff of the Department of Nuclear Medicine of the Middlesex Hospital Medical School. The growth hormone assay was originally set up by Dr H. S. Jacobs. Dr S. Franks performed the prolactin assays, and Dr P. R. Daggett the integrated hormone measurements. I wish also to acknowledge my indebtedness to my registrars and house officers who have helped in the investigation of these patients.
